Inclusion Criteria:
1. Age 20 years or older, at the time of acquisition of informed consent
2. Histologically confirmed metastatic or unresectable GIST with CD117(+), DOG-1(+), or
mutation in KIT or PDGFRαgene
3. Patients who failed to at least imatinib, sunitinib, and regorafenib (disease
progression and/or intolerance) (Note: The number of previous treatment is not
limited. Previous use of other chemotherapies such as tyrosine kinase inhibitor (TKI),
or any other chemotherapeutic agents concurrently used with imatinib, sunitinib, and
regorafenib is permitted.)
Disease progression is defined as follows:
- Increase of tumor size by more than 20% according to RECIST version 1.1,
- Appearance of a definite new lesion (excluding small cystic new lesions in the
liver within 6 months of starting TKIs)
- A new solid nodule with in a cystic mass, or
- Increase of the size (> 20%) of previously existing solid nodule within a cystic
mass
Intolerability to previous TKI is defined as follows:
- Less than 75% of medication compliance due to non-hematological toxicity of grade
2 or above despite dose reduction to a one-step lower level (300 mg/day for
imatinib; 37.5 mg/day for 4-week on/2-week off schedule or 25 mg/day with
continuous schedule for sunitinib; and 120 mg/day for regorafenib)
- Febrile neutropenia, Grade 4 neutropenia lasting >6 days, Grade 4
thrombocytopenia, Grade 3 thrombocytopenia accompanied with clinically
significant hemorrhage, Grade 3-4 or intolerable continuous Grade 2
non-hematologic toxicity despite dose reduction to one-step lower level as
described above
4. P-glycoprotein immunohistochemistry (IHC) H-score ≤250 in tumor tissue obtained after
failure of previous treatment for GIST, including imatinib, sunitinib, and regorafenib
- H-score is a sum of the multiplications of each intensity score (0-3) measured by
the IHC and its corresponding proportion (0-100) of tumor cells (a score of
0-300).
- Intensity is evaluated as 0 (negative), 1 (weak), 2 (moderate), or 3 (strong).
- e.g.) If a proportion with an intensity of 3 is 40%, proportion with an intensity
of 2 is 30%, proportion with an intensity of 1 is 20%, and proportion with an
intensity of 0 is 10%, H-score is 200 (3x40 + 2x30 + 1x20).
5. ECOG performance status of 0~2
6. Toxicity of all previous treatments is recovered to Grade 0 or Grade 1 according to
NCI-CTCAE Version 5.0
7. At least one measurable lesion by RECIST Version 1.1.
8. Adequate bone marrow, hepatic, renal, and other organ functions
- Neutrophil ≥ 1,500/mm3
- Platelet ≥ 100,000/mm3
- Hemoglobin ≥ 8.0 g/dL
- Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
- AST/ALT < 3 x ULN without liver metastases or AST/ALT < 5 x ULN with liver
metastases
- Creatinine ≤1.5 x ULN
9. Expected life expectancy of ≥12 weeks
10. Washout period of previous TKIs or chemotherapy for more than 4 times the half life
(Seven days of washout period is enough for imatinib, sunitinib, and regorafenib)
11. Patients who signed informed consent
Exclusion Criteria:
1. A pregnant or nursing woman, or a woman of childbearing age
2. A woman or a man who is not willing to use effective contraception during study drug
administration or within 3 months following end of study drug administration. Barrier
method should be used both in men and women during study drug administration and up to
3 months following end of administration. Oral preparations, implants, or
contraceptive injections are not deemed as effective contraceptions in this study
since these may be influenced by cytochrome P450 interactions.
Women of childbearing age are defined as sexually mature women who have not received
hysterectomy or do not undergo natural menopause for more than 12 consecutive months,
at least (that is, who had the menses within previous 12 months), and must be shown to
be negative in serum or urine pregnancy test within 14 days before starting paclitaxel
treatment.
3. If a patient falls under one of the followings within 6 months prior to recruitment:
myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery
bypass, NYHA class III or IV congestive heart failure, stroke or transient ischemic
attacks, serious cardiac arrhythmia requiring treatment
4. 4) Uncontrolled infection
5. Diabetes with sign of clinically significant peripheral disease
6. Acute or chronic liver disease and all chronic hepatic impairments (a patient with
stable chronic hepatitis B is eligible.)
7. Uncontrolled gastrointestinal toxicity (nausea, diarrhea, vomiting) accompanied with
toxicity above NCI CTCAE Grade 2
8. Other severe, acute, or chronic medical or psychiatric condition or laboratory
abnormality that may increase the risk associated with study participation or study
drug administration or may interfere with the interpretation of study results and, in
the judgment of the investigator, would make the subject inappropriate for this study
9. A patient who has hemorrhage that is thought to threaten one's life requiring
transfusion or endoscopic or surgical intervention, or Grade 3 or 4 hemorrhage within
3 months prior to treatment with study drug
10. Major surgery ≤ 28 days prior to starting study drug or who have not recovered from
side effects of such therapy If diagnosis of HIV infection is known (HIV test is not
obligatory)
11. Known diagnosis of HIV infection (HIV testing is not mandatory)
12. History of another primary malignancy that is currently clinically significant or
currently requires active intervention
13. A patient with brain metastasis when evaluated by radiological imaging (e.g. CT, MRI)
if there is a symptom that is clinically suspected of brain metastasis
14. Alcohol or substance abuse disorder
